Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R9.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R4.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R6.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R8.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R3.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R5.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R7.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R1.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R10.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R15.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R17.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R13.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R11.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R14.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R12.htm
XML - IDEA: XBRL DOCUMENT - CEREBAIN BIOTECH CORP.R16.htm
EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - CEREBAIN BIOTECH CORP.f10q123111_ex31z1.htm
EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - CEREBAIN BIOTECH CORP.f10q123111_ex32z1.htm
10-Q - DECEMBER 31, 2011 10Q - CEREBAIN BIOTECH CORP.f10q123111_10q.htm
v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
Dec. 31, 2011
Jun. 30, 2011
Current assets:    
Cash and cash equivalents $ 1,176 $ 746
Total current assets 1,176 746
Long term assets:    
Computer equipment, net 784 1,212
Patent rights 82,098 75,900
Total long term assets 82,882 77,112
Total assets 84,058 77,858
Current liabilities:    
Accounts payable 63,896 7,649
Related party payables 307,174 388,110
Income taxes payable 2,200 1,800
Notes payable to stockholders 160,000 5,490
Total current liabilities 533,270 403,049
Total liabilities 533,270 403,049
Stockholders deficit    
Preferred stock ($0.001 par value: 1,000,000 shares authorized; none issued and outstanding) 0 0
Common stock ($0.001 par value: 74,000,000 shares authorized; 4,952,800, and 4,708,000 shares issued and outstanding at December 31, 2011, and June 30, 2011, respectively) 4,953 4,708
Additional paid in capital 710,431 174,792
Deficit accumulated during the development stage (1,164,596) (504,691)
Total stockholders deficit (449,212) (325,191)
Total liabilities and stockholders deficit $ 84,058 $ 77,858